Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid

Abstract We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Neelima Vidula, Sally Greenberg, Laura Petrillo, Jimmy Hwang, Michelle Melisko, Andrei Goga, Mark Moasser, Mark Magbanua, John W. Park, Hope S. Rugo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3a9e793b4485485687e39189dbcf79b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a9e793b4485485687e39189dbcf79b3
record_format	dspace
spelling	oai:doaj.org-article:3a9e793b4485485687e39189dbcf79b32021-12-02T14:54:51ZEvaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid10.1038/s41523-021-00323-82374-4677https://doaj.org/article/3a9e793b4485485687e39189dbcf79b32021-09-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00323-8https://doaj.org/toc/2374-4677Abstract We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at baseline, and 12 and 24 months of ZOL. Complete DTC response (<4 DTC/mL), serial CTCs, survival, recurrence, and toxicity were determined. Forty-five patients received ZOL. Median baseline DTC was 13.3/mL. Significant reduction in median DTC occurred from baseline to 12 months, and 24 months. Complete DTC response was seen in 32% at 12 months, and 26% at 24 months. Nine patients developed recurrence. Baseline DTC > 30/mL and CTC > 0.8/mL were significantly associated with recurrence and death. Serial reduction in DTCs occurred. Higher baseline DTC > 30/mL and CTC > 0.8/mL correlated with recurrence and death.Neelima VidulaSally GreenbergLaura PetrilloJimmy HwangMichelle MeliskoAndrei GogaMark MoasserMark MagbanuaJohn W. ParkHope S. RugoNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Neelima Vidula Sally Greenberg Laura Petrillo Jimmy Hwang Michelle Melisko Andrei Goga Mark Moasser Mark Magbanua John W. Park Hope S. Rugo Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
description	Abstract We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at baseline, and 12 and 24 months of ZOL. Complete DTC response (<4 DTC/mL), serial CTCs, survival, recurrence, and toxicity were determined. Forty-five patients received ZOL. Median baseline DTC was 13.3/mL. Significant reduction in median DTC occurred from baseline to 12 months, and 24 months. Complete DTC response was seen in 32% at 12 months, and 26% at 24 months. Nine patients developed recurrence. Baseline DTC > 30/mL and CTC > 0.8/mL were significantly associated with recurrence and death. Serial reduction in DTCs occurred. Higher baseline DTC > 30/mL and CTC > 0.8/mL correlated with recurrence and death.
format	article
author	Neelima Vidula Sally Greenberg Laura Petrillo Jimmy Hwang Michelle Melisko Andrei Goga Mark Moasser Mark Magbanua John W. Park Hope S. Rugo
author_facet	Neelima Vidula Sally Greenberg Laura Petrillo Jimmy Hwang Michelle Melisko Andrei Goga Mark Moasser Mark Magbanua John W. Park Hope S. Rugo
author_sort	Neelima Vidula
title	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
title_short	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
title_full	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
title_fullStr	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
title_full_unstemmed	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
title_sort	evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3a9e793b4485485687e39189dbcf79b3
work_keys_str_mv	AT neelimavidula evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT sallygreenberg evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT laurapetrillo evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT jimmyhwang evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT michellemelisko evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT andreigoga evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT markmoasser evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT markmagbanua evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT johnwpark evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT hopesrugo evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid
_version_	1718389377845952512

Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid

Ejemplares similares